

Response: Thanks for the valuable comments. The study design was retrospective.
The institutional review board agreed with waiver of informed consent of treatment.



佛教慈濟醫療財團法人台北慈濟醫院
人體試驗審查委員會臨床試驗案同意函

臨床試驗案名稱：周邊血液中嗜酸性白血球增多對於住院的慢性阻塞性肺病病人關於全身性類固醇的使用與再住院次數的影響

計畫主持人：吳智偉

案件編號 (包括版本)：08-X-094 (第一版) (本院編號)

計畫書版本：第一版, Sep., 19, 2019

受試者同意書版本：Waiver

個案報告版本：Nil.

上述臨床試驗案於(西元)2019年9月19日經本院人體試驗審查委員會審查通過,特此證明。
本會組織與執行皆遵守 ICH-GCP 規範。

本臨床試驗案執行期間自 2019 年 9 月 3 日至 2021 年 9 月 2 日
本同意函有效期間自核發日起一年,屆時須依規定繳交必要之文件,即核發展延同意函。

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Institutional Review Board Approval Letter

Protocol Title: Impact of peripheral eosinophilia on systemic steroid administration and numbers of readmission in hospitalized patients with COPD

Principal Investigator: Wu, Chih-Wei

Protocol No.: 08-X-094 (version 1) (Of this Institution)

Protocol: version 1, Sep., 19, 2019

Inform consent form: Waiver

Case report form: Nil.

The above study has been approved by the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Institutional Review Board on Sep., 19, 2019. The constitution and operation of this review board are according to the guidelines of ICH-GCP.



The above study conduction time is from Sep., 3, 2019 to Sep., 2, 2021

This approval letter is valid for 1 year from issued date. An approval extension letter will be issued after required documents are received by this IRB.

人體試驗審查委員會 主任委員

(簽名) 廖朝崧

日期：(西元) 2019 年 9 月 20 日

Chairman, Institutional Review Board

Chiau-Suong Liao
(Chiau-Suong Liao)

Date (M/D/Y): 9 / 20 / 2019